Sodium-Glucose Co-Transporter 2 (SGLT2): Revolutionizing Diabetes Treatment

Author(s): Olivera Lam

Sodium-glucose co-transporter 2 (SGLT2) inhibitors have emerged as a game-changer in the management of diabetes mellitus. These medications target the SGLT2 protein in the kidneys, reducing glucose reabsorption and promoting its excretion through urine. By working independently of insulin, SGLT2 inhibitors offer unique benefits, including improved glycemic control, weight loss, blood pressure reduction, renal protection, and cardiovascular benefits. They have also shown potential in type 1 diabetes management. However, it is essential to consider safety considerations, such as an increased risk of genitourinary infections. This article explores the remarkable impact of SGLT2 inhibitors on diabetes treatment and their implications for patient care.